CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 65 enrolled
Drug / intervention
Bevacizumab +1 moredrug
Likely dose
Not stated in record
Key inclusion· 7
  • ✓Unresectable advanced or metastatic non-clear cell RCC including papillary, chromophobe, collecting duct, medullary, translocation, unclassified types, or clear cell with >20% sarcomatoid features
  • ✓Age ≥18 years
  • ✓ECOG performance status ≤2
  • ✓Measurable disease by RECIST v1.1
Key exclusion· 10
  • ✕Prior treatment with anti-PD-1, anti-PD-L1, anti-CTLA-4, or CD137 agonist antibodies
  • ✕Prior bevacizumab therapy
  • ✕Small molecule kinase inhibitor within 2 weeks or other anticancer therapy (including monoclonal antibodies, cytokine) within 4 weeks of enrollment
  • ✕Systemic immunosuppressive medications (prednisone, dexamethasone, cyclosporin, azathioprine, methotrexate, thalidomide, TNF inhibitors, hydroxychloroquine) within 2 weeks of first dose

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02724878
NCT02724878Phase 2Completed
CompareCT.gov

Phase II Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Dana-Farber Cancer Institute·interventional·Posted Mar 31, 2016·Updated Feb 13, 2025

In Brief

A Phase 2 clinical trial evaluating Bevacizumab and Atezolizumab for Advanced Non-Clear Cell Kidney Cancer. Completed, enrolled 65 participants across 4 sites.

Detailed Summary

This research study is studying the combination of Atezolizumab and Bevacizumab as a possible treatment for Advanced Non-Clear Cell Kidney Cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Non-Clear Cell Kidney Cancer
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 31, 2016
Enrollment StartJul 15, 2016
Primary CompletionNov 13, 2019
Study CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 10.3 years ago

Interventions

Bevacizumabdrug

Atezolizumabdrug